DPP-3 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human DPP-3 (UniProt Q9NY33), expressed in HEK293 cells. Full-length 737-aa cytosolic metalloprotease for activity assays, inhibitor profiling, and antibody validation.
Expression system
HEK293
Cat. #
REC-DPP3

In stock

SKU
REC-DPP3
$498.00

Target Overview

DPP-3 (dipeptidyl peptidase 3; UniProt Q9NY33) is a cytosolic zinc metalloprotease of 737 amino acids that sequentially removes dipeptides from the N-terminus of oligopeptide substrates. It is encoded by the DPP3 gene and classified under EC 3.4.14.4. This recombinant is produced in HEK293 cells, providing mammalian post-translational processing — glycosylation and folding — relevant to activity-based studies of the native enzyme. In vitro, DPP-3 cleaves angiotensin II, Leu-enkephalin, Met-enkephalin, and the fluorogenic substrate Arg-Arg-β-naphthylamide (Arg-Arg-βNA), making it well suited to fluorometric activity assays where substrate hydrolysis is monitored continuously. Researchers use the recombinant protein to establish enzyme kinetics (Km, kcat, Vmax), to determine inhibitor IC50 values in dose-response formats, and to validate substrate selectivity across peptide libraries. Because DPP-3 circulates at measurable levels under pathological conditions, quantitative immunoassay development — ELISA standard curve generation, lateral-flow calibration — requires a well-characterised, soluble recombinant antigen. This preparation serves that purpose directly. Researchers requiring a positive-control antigen for Western blot or immunohistochemistry can pair this recombinant with the Triple Point Biologics matched anti-DPP3 antibody (RP-DPP3), which has been validated for both applications. The HEK293 expression background is preferred over E. coli-derived material for folding-sensitive metalloprotease work, where misfolded or aggregated protein can confound kinetic constants and inhibitor binding measurements. Researchers conducting biophysical characterisation — thermal shift, surface plasmon resonance, or isothermal titration calorimetry — should note the mammalian origin when interpreting binding data.

Background

DPP-3 (dipeptidyl peptidase III; EC 3.4.14.4; gene DPP3) is a zinc-dependent metalloprotease that resides in the cytosol and degrades short bioactive peptides by removing successive N-terminal dipeptides. Its characterised substrates include angiotensin I and II, the opioid peptides Leu-enkephalin and Met-enkephalin, and synthetic fluorogenic substrates such as Arg-Arg-β-naphthylamide. Cleavage of angiotensin by DPP-3 positions the enzyme within the renin–angiotensin system, while enkephalin degradation connects it to endogenous opioid signalling pathways; both areas are active subjects of basic research into cardiovascular and pain-related biology. DPP-3 has been characterised as a research target in acute organ dysfunction. Elevated circulating DPP-3 levels have been reported in critically ill patients, and the enzyme's degradation of angiotensin II has been investigated as a mechanism contributing to haemodynamic instability in this context. This biology motivated the development of DPP-3-neutralising antibody strategies as experimental tools, and several recent publications describe the non-clinical and early clinical characterisation of Procizumab (invobenitug), a humanised antibody targeting circulating DPP-3 (Genest M et al., MAbs, 2026; PMID 42165222). Recombinant DPP-3 has been used as the reference antigen in such programmes — for binding affinity measurements, neutralisation assays, and pharmacodynamic enzyme-activity readouts. Beyond the cardiovascular context, DPP-3 expression has been studied in the setting of bone biology; a 2026 study reported that DPP3 deficiency affects bone quality and sensitises animals to metabolic alterations (Bevacqua E et al., Bone, 2026; PMID 42208752), expanding the experimental contexts in which the enzyme is being characterised. DPP-3 has also been studied in inflammatory skin disease, where a post-translational modification signature analysis identified DPP3 expression as associated with inflammatory pathway activation in psoriasis lesional tissue (Ye Z et al., Gene, 2026; PMID 42173459). Across these research contexts, the recombinant protein supports mechanistic biochemistry: direct measurement of peptidase activity, competitive inhibitor profiling, antibody epitope mapping, and generation of calibration standards for quantitative DPP-3 immunoassays. Researchers at Triple Point Biologics' partner laboratories have used the matched anti-DPP3 antibody (RP-DPP3) alongside this recombinant for Western blot confirmation of expression in cell and tissue lysates.

Applications

  • Fluorometric peptidase activity assay using Arg-Arg-β-naphthylamide (Arg-Arg-βNA) as substrate
  • Enzyme kinetics determination (Km, kcat, Vmax) with angiotensin II or enkephalin substrates
  • Inhibitor IC50 and dose-response profiling in competitive inhibition formats
  • ELISA standard curve generation for quantitative DPP-3 immunoassays
  • Antibody validation positive control for Western blot (pair with RP-DPP3 anti-DPP3 antibody)
  • Surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding affinity measurements with anti-DPP3 antibodies or inhibitor candidates
  • Thermal shift (DSF) and biophysical characterisation of DPP-3 folding and ligand-induced stability
  • Substrate selectivity profiling across peptide libraries by mass spectrometry-based cleavage assay

References

  1. Bevacqua E et al. DPP3 deficiency impacts bone quality and sensitizes to metabolic alterations. Bone. 2026. doi:10.1016/j.bone.2026.117951. PMID: 42208752.
  2. Ye Z et al. Novel post-translational modification learning signature reveals DPP3 promotes progression of psoriasis by enhancing inflammatory activation. Gene. 2026. doi:10.1016/j.gene.2026.150225. PMID: 42173459.
  3. van Lier D et al. Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates. MAbs. 2026. doi:10.1080/19420862.2026.2672800. PMID: 42166148.
  4. van Lier D et al. Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial. MAbs. 2026. doi:10.1080/19420862.2026.2671468. PMID: 42165327.
  5. Genest M et al. Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3. MAbs. 2026. doi:10.1080/19420862.2026.2675077. PMID: 42165222.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight band should I expect for recombinant DPP-3 on SDS-PAGE or Western blot?

The DPP-3 polypeptide (UniProt Q9NY33) is 737 amino acids with a predicted unmodified MW of ~83 kDa. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation adds variable mass; expect a diffuse band migrating at approximately 90–100 kDa under denaturing conditions. A smear or doublet in this range is normal and reflects heterogeneous glycosylation, not degradation. If you observe a sharp ~83 kDa band, partial deglycosylation during sample prep is the likely cause. Running 100–200 ng per lane is sufficient to visualize by Coomassie or silver stain.

Is recombinant DPP-3 full-length or a truncated active fragment, and does it require any processing to become active?

This recombinant corresponds to the full-length human DPP-3 sequence (residues 1–737, UniProt Q9NY33). DPP-3 is a cytosolic zinc metalloprotease that does not undergo signal-peptide cleavage or propeptide removal; the full-length form is the catalytically active species. No additional processing or activation step is required after thawing. Catalytic activity depends on the coordinated zinc ion at the HEXXGH motif; avoid chelating agents such as EDTA or EGTA in assay buffers, as even low micromolar concentrations will inhibit the enzyme irreversibly.

Which fluorogenic substrate works best for a DPP-3 activity assay, and what are recommended reaction conditions?

Arg-Arg-β-naphthylamide (Arg-Arg-βNA) is the standard fluorogenic substrate for DPP-3 activity assays. Use 50–200 µM substrate in 50 mM Tris-HCl pH 7.5, 150 mM NaCl at 37°C; β-naphthylamine release is monitored continuously at Ex 335 nm / Em 410 nm. Published Km values for this substrate are in the 50–150 µM range depending on pH and salt. Start with 5–20 nM recombinant DPP-3 per reaction and optimize enzyme concentration to keep initial-rate conditions linear (< 15% substrate consumed over the assay window).

Can I use recombinant DPP-3 to measure inhibitor IC50 values, and what starting enzyme concentration is recommended?

Yes. For IC50 determination, titrate inhibitor across 8–10 concentrations spanning at least 3 log units and incubate with enzyme for 15–30 minutes at room temperature before adding substrate. Use 5–10 nM recombinant DPP-3 with 100 µM Arg-Arg-βNA in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 37°C. Keep enzyme concentration well below the Km to avoid tight-binding artifact in apparent IC50 calculations. Include 0.01–0.05% BSA to reduce non-specific adsorption to plate surfaces, particularly at low nanomolar inhibitor concentrations. Run each compound in duplicate across at least two independent plates.

Does recombinant DPP-3 cleave angiotensin II, and how do I confirm peptidase activity on natural substrates?

DPP-3 cleaves angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) by sequentially removing N-terminal dipeptides. Activity on angiotensin II can be confirmed by reverse-phase HPLC or LC-MS/MS monitoring the disappearance of the parent octapeptide and appearance of the Val-Tyr-Ile-His-Pro-Phe hexapeptide product. Use 1–5 µM angiotensin II with 50–100 nM recombinant DPP-3 in 50 mM Tris-HCl pH 7.5, 150 mM NaCl at 37°C. Leu-enkephalin and Met-enkephalin are also validated substrates if you need shorter peptides for parallel selectivity profiling.

How much recombinant DPP-3 should I load as a Western blot positive control when validating antibody RP-DPP3?

Load 50–200 ng of recombinant DPP-3 per lane alongside your cell lysate samples. At 100 ng, the matched rabbit polyclonal antibody RP-DPP3 (see /anti-dpp-3-rabbit-polyclonal-antibody) produces a clear band in the 90–100 kDa region under standard ECL conditions. Because the recombinant is HEK293-expressed, it carries the same glycosylation pattern as endogenous human DPP-3, so the recombinant band co-migrates directly with the endogenous band in human cell lysates — no band-shift artifact to account for during validation.

Can I use recombinant DPP-3 paired with antibody RP-DPP3 for antibody specificity validation or immunoprecipitation input controls?

Yes, this is a straightforward pairing. The recombinant protein (REC-DPP3) and antibody (RP-DPP3) were developed in the same lab and are guaranteed compatible for Western blot positive controls. For IP input controls, spike 100–500 ng recombinant DPP-3 into lysate before immunoprecipitation with RP-DPP3 to confirm pull-down efficiency. For dot-blot or slot-blot specificity checks, 10–50 ng is sufficient. Note that RP-DPP3 is a rabbit polyclonal; if your secondary antibody or blocking conditions require optimization, the recombinant provides a reliable, concentration-defined positive control for that troubleshooting.

How should I store and handle recombinant DPP-3 to preserve activity, and what is its shelf life?

Recombinant DPP-3 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — no reconstitution required. Store at -20°C in single-use aliquots immediately upon receipt. Repeated freeze-thaw cycles progressively reduce metalloprotease activity; plan aliquot sizes to match your typical experiment. Shelf life is 12 months at -20°C when handled correctly. For same-day experiments, thawed enzyme can be held on ice for up to 4 hours without significant activity loss. Avoid diluting into buffers containing EDTA, EGTA, or high concentrations of reducing agents, as these chelate the catalytic zinc and inactivate the enzyme.

Validation imagery coming soon

Western blot validation figures for REC-DPP3 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →